Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
{{output}}
Background: We analyzed outcomes and survival predictors in three WSG randomized de-escalation trials (ADAPT-HR-/HER2+, ADAPT-TP, TP-II) in HER2+ early breast cancer (eBC) investigating short (12-week) neoadjuvant treatments with... ...
